Paresh P. Email & Phone Number

Dublin, Ie

Promoted to develop strategies and lead special projects for LYBALVI®, a schizophrenia and bipolar 1 disorder drug• Led the development of a new organizational capability with its first-ever patient voucher program ^ Developed the strategic business case for a new voucher product that included revenue and cost projections yielding a “go decision” for development ^ Designed product offering requirements maximizing customer experience ^ Established a governance and project workstream framework and selected members for an oversight committee, workstreams leads, and sub-teams building in project accountability ^ Defined sub-team objectives laddering to the overall program objectives focusing efforts for workstream leaders and their team members ^^ Stakeholders included Legal, Marketing Operations, Business Analysts, IT, Field Training, Sales, Data Analytics, and Vendors ^ Spearheaded multiple cross-functional teams from inception to rollout and measurement ensuring continuity and quality of product development ^^Stages included RFP, Vendor Selection, Contract Negotiation, Product Business Requirements, CX optimization, IT Implementation, Launch, and KPI reporting ^ Presented monthly to the oversight committee outlining project progress and risks ensuring team accountability to project completion• Re-positioned LYBALVI using internal and external insights crystalizing the value proposition and unifying the organization’s vernacular for consistent messaging aligned to strategy• Identified key business questions and synthesized insights from analytics, market research, advisory boards, sales, and competitive intelligence that directly informed strategic decisions• Created the omnichannel strategy and business rules for the brand increasing sales force efficiency and sales

Dublin, Ie

Promoted to a launch marketing role to develop the HCP messaging strategy and launch campaign for LYBALVI® • Assembled all parts of the organization to brand planning for launch leading to organizational buy-in and direction • Defined the launch early adopter segmentation yielding a 10X greater conversion ratio upon calls vs non-early adopters• Led the launch messaging strategy, asset creation, medical-legal approval, OPDP strategy, and rollout of promotional collateral both for the sales force and for digital promotion yielding an optimal and concise brand story• Facilitated monthly forum with field sales to collaborate on how to grow the business yielding refinement in strategies and tactics

Dublin, Ie

Hired to explore lifecycle management opportunities for a depression medication that received a CRL letter• Assessed the impact of various launch scenarios by leading market research and forecasting yielding a “no-go” decision to re-file• Conducted early assessments of potential new indications by estimating revenue forecasts and NPVs resulting in a prioritization of potential investment• Competitive pipeline monitoring via secondary research and conference surveillance informing the potential launch landscapes

Product marketing expert in charge of operations, soliciting client engagements, and executing to client satisfaction • Engagements included serving clients in pharmaceuticals, alternative health, academia, and technology firms in the areas of Product Strategy, Market Research, Scientific Communications, and Capital Fundraising

Tempe, Az, Us

Joined to develop new THC and CBD formulations for medical applications and evaluate new processes. Had 3 direct reports• Increased operating revenue by 16% by leading a 20-person organization • Led technology and financial assessments for product licensing deals attracting B2B customers• Developed three new product lines in an entrepreneurial environment expanding the company pipeline• Participated as an industry advisor with county and state authorities in developing regulations creating consistent standards for product labeling- Conceived, designed, and executed original research that was later published [Troutt, W.D., DiDonato, M.D. (2017), “Carbonyl Compounds Produced by Vaporizing Cannabis Oil Thinning Agents”, J. Alt. & Com. Med. 23, (11)]

Marlborough, Ma, Us

Evaluated and launched lifecycle opportunities for neurological medications• Launched a new monotherapy indication for partial-onset seizures within 10 months after the initial launch increasing product value by an additional 5%• Commercialized a branded APTIOM lab assay with Quest Diagnostics in 6 months to coincide with the initial launch maximizing product adoption for neurologists• Assessed commercial viability for external business development and lifecycle opportunities with a European licensor by conducting forecasts, NPV analyses, market research, and leading cross-functional meetings advancing product lifecycle opportunities

Bagsværd, Dk

Set up the business framework to launch SAXENDA and what is now the first GLP-1 medication product for obesity. Had 2 direct reports• Formulated the launch strategy by creating the forecast and leading all market research in tandem with chairing the Pipeline Asset Commercialization team and passing a McKinsey strategy challenge• Achieved strategic alignment between Global and the US affiliate by integrating traditional market research and non-traditional insight generation from KOLs & Advocacy organizations• Developed pre-launch core story, awareness campaign, core creative, positioning, and messages for SAXENDA as a member of the Global Marketing team resulting in a successful launch of a new drug

San Antonio, Tx, Us

STRATTICE - regenerative tissue-Launched STRATTICE to plastic surgeons and patients with a 138-person account team and 1 direct report-Doubled sales run rate over two quarters to meet revenue objectives designing a sales incentive program to align with market conditions-Launched patient website RenewingYou.com, developed white paper case studies on surgical technique, and designed customer brochures (print and digital)

Rahway, New Jersey, Us

COZAAR & HYZAAR- hypertension-Developed the patent expiry pull through strategy to maximize revenue for a $3B franchise -Executed market research projects across all customers including physician, patient, managed care, and pharmacy customers

-Booked and executed over $500,000 in pre-launch consulting services across a diverse set of therapeutic categories and customers (managed care, patients, health care professionals)-Other Clients included GSK, Novartis, Pfizer, Astra Zeneca, Genentech

Rahway, New Jersey, Us

Marketing ManagerFOSAMAX - osteoporosis-Launched FOSAMAX PLUSD, new clinical data, and counter-tactics to blunt the uptake of a new entrant to reverse the declining market share-Led a cross-functional team of 8 and designed the franchise's $18MM integrated promotional plan to effectively compete against in-class competition towards meeting an annual revenue target of $3B

Rahway, New Jersey, Us

Marketing Research ManagerFOSAMAX – osteoporosis-Identified the optimal message campaign for the successful launch of FOSAMAX PLUSD across three market events within a 6-month time frame resulting in a turnaround of share growth vs. prior share losses of 6% over 12 months-Designed the franchise's $4.4 MM research plan to assess the launch of FOSAMAX PLUSD, the impact of new entrants, and the feasibility of market development options

Rahway, New Jersey, Us

Professional Sales RepresentativeSINGULAIR, SINGULAIR AR, ZOCOR, ZETIA, VIOXX, – respiratory, cardiovascular, pain-Created new standard for region and district territory level targeting analyses-Launched Singulair AR and ZETIA

Master Of Business Administration - Mba, Strategy, Marketing, Finance

Bs, Chemical Engineering/Biomedical Engineering